Renovaro Inc. (NASDAQ:RENB - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 3,870,000 shares, an increase of 27.7% from the November 30th total of 3,030,000 shares. Based on an average daily volume of 869,400 shares, the days-to-cover ratio is currently 4.5 days. Currently, 5.0% of the shares of the company are short sold.
RENB traded down $0.04 during trading on Tuesday, hitting $0.84. 366,774 shares of the stock were exchanged, compared to its average volume of 628,313. Renovaro has a 1-year low of $0.40 and a 1-year high of $5.25. The stock has a fifty day moving average price of $0.91 and a two-hundred day moving average price of $0.91. The firm has a market capitalization of $132.61 million, a P/E ratio of -0.87 and a beta of 0.65.
Renovaro (NASDAQ:RENB - Get Free Report) last announced its earnings results on Thursday, October 10th. The company reported ($0.45) EPS for the quarter.
A number of large investors have recently bought and sold shares of RENB. Barclays PLC increased its stake in Renovaro by 315.7% in the 3rd quarter. Barclays PLC now owns 69,531 shares of the company's stock valued at $34,000 after purchasing an additional 52,804 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Renovaro by 347.6% in the third quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company's stock valued at $45,000 after buying an additional 72,230 shares in the last quarter. Rhumbline Advisers acquired a new position in shares of Renovaro during the 2nd quarter worth $79,000. Bank of New York Mellon Corp purchased a new stake in shares of Renovaro in the 2nd quarter worth about $220,000. Finally, State Street Corp grew its stake in Renovaro by 3.8% in the 3rd quarter. State Street Corp now owns 1,323,832 shares of the company's stock valued at $640,000 after acquiring an additional 48,114 shares during the last quarter. Hedge funds and other institutional investors own 71.41% of the company's stock.
Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Renovaro, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Renovaro wasn't on the list.
While Renovaro currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.